Skip to content
WorkResearchAboutContactGitHub
All research

Product & Strategy

Cipla: A Point of Care Diagnostics Business

Turning prescriber reach into test and treat, on ₹954 Cr of capital, 10% of net cash

Read the PDF Download
Domain
Product & Strategy
Kind
Cipla Ascend Season 2 · Round 1 submission
Length
5 pp · 0.5 MB

What it found

₹615 Cr
FY32 revenue, base case, on labelled assumptions
19%
FY32 EBITDA margin, breakeven in FY30
26 of 30
point of care kits in a five segment screen

Point of care kits

26 of 30

Lung clinics

20 of 30

Path labs

17 of 30

Multispecialty hospitals

13 of 30

Implants and consumables

10 of 30

Five healthcare segments scored on growth, margin, capital needs, channel fit, price freedom and pharma pull, out of 30. The scores are judgement readings of the evidence rather than survey data.

Source: Finding 1; the deck's first slide after the title

Cipla: A Point of Care Diagnostics Business, first page

Overview

A Round 1 case submission for Cipla Ascend Season 2, recommending that Cipla build a point of care diagnostics business on its prescriber reach. The base case reaches ₹615 Cr of FY32 revenue (range ₹307 to 1,048 Cr) at a 19% EBITDA margin, with breakeven in FY30, on ₹954 Cr of capital over five years. Judgement scores and model inputs are labelled assumptions, and the plan starts with a 50 clinic pilot to replace them with measured values.

Findings

  1. Point of care is where a pharma channel wins. On six criteria it scores 26 of 30, against 20 for lung clinics, 17 for path labs, 13 for multispecialty hospitals and 10 for implants and consumables

  2. India is the engine. In Q2 FY27 India grew 12% while group revenue fell 2% and North America fell 19%, and net cash of ₹9,823 Cr covers the five year plan 10.3 times

  3. The base case stays below listed peers. Its 19% margin compares with Molbio at 22.2%, Metropolis at 24.4% and Dr Lal PathLabs at 28.3%, with cartridges reaching 63% of revenue and ₹187 Cr a year of pharma revenue pulled through by FY32

  4. Idle analysers are the risk to manage first. Molbio's utilisation is 42.3%, so analysers are placed only where clinics commit to 3 tests a day

  5. Capital is released through gates. A 50 clinic pilot reads out by March 2027, 4,000 analysers at 3.5 tests a day are due by FY29, and any acquisition waits until after breakeven